Most patients who received TZIELD experienced mild lymphopenia, a common adverse event that often resolved by Week 62
Lymphocyte count began to recover after Day 5 and returned to baseline by Week 6 in most patients.
Monitor white blood cell counts during the 2-week treatment period. If prolonged severe lymphopenia
(<500 cells per mcL lasting 1 week or longer) develops, discontinue TZIELD.
Average lymphocyte count during TN-10 study1,2
Average absolute lymphocyte counts reached a nadir by Day 5 and then began to recover and returned to baseline by Week 6 in most patients
![A chart showing the average absolute lymphocyte counts reached a nadir by day 5 and then began to recover and returned to baseline by week 6 in most TZIELD® (teplizumab-mzwv) patients](/images/clinical-data/safety_average_lymphocyte_count.svg)